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Rapport de synthèse 
L'homocystéine est un molécule potentiellement atherogénique et est considéré comme facteur de 
risque indépendant pour les maladies cardiovasculaires. Pour les patients avec une maladie rénale 
chronique ou en général avec une fonction rénale diminuée le taux d'homocystéine dans le sérum est 
élevé. L'acide urique est associé avec un risque augmenté de développer une maladie rénale et prédit 
la mortalité pour les patients avec une maladie rénale chronique. 
Le but de cette étude était d'évaluer l'association entre des taux sériques d'homocystéine élevés est la 
présence d'une fonction rénale diminuée, exprimé par une filtration glomérulaire diminuée ou une 
albuminurie dans une sélection de la population de Lausanne. Nous avons aussi investigué l'effet de 
l'acide urique sur cette relation. Pour évaluer si l'association entre l'homocystéine est l'albuminurie 
pourra être causal, nous avons en même temps investigué l'association entra l'albuminurie est le 
polymorphisme du gène de la methylènetetrafolate réductase (MTHFR) fortement corrélé avec les 
taux sériques de l'homocystéine. 
L'étude CoLaus est transversale et basée sur la population. Elle représente une sélection aléatoire, non 
stratifié de la population générale de la ville de Lausanne, Suisse, âgée 35-75 ans (n=56.694). 5913 
personnes étaient incluses dans l'analyse. 
La prévalence de l'albuminurie augmente dans les catégories de taux sériques croissants 
d'homocystéine. L'acide urique est associé avec la concentration sérique de l'homocystéine. 
Hyperhomocystéinémie et des taux sérique d'acide urique augmentés sont associés avec 
l'albuminurie, indépendant de l'hypertonie et du diabète. 
Dans cette étude basée sur une large population, l'association entre des taux sérique elevés 
d'homocystéine et la prévalence augmentée de l'albuminurie est indépendante de la fonction 
glomérulaire, indiquant que cette association n'est pas simplement la conséquence de la fonction 
rénale réduite. Hyperhomocystéinémie est associé avec un risque doublé pour une albuminurie, ce 
qu'est similaire au risque associé à l'hypertonie ou au diabète type 2. Cette association est 
indépendante de l'acide urique. Ce résultat suggère que l'hyperhomocystéinémie est un marqueur 
indépendant des la dysfonction rénale. Individus avec le polymorphisme du MTHFR associé avec des 
concentrations sériques élevées d'homocystéine sont associé avec un risque augmenté pour une 
albuminurie. Tous ces résultats supportent l'hypothèse que l'homocystéine cause des dommages 
rénaux. 
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Hyperhomocysteinemia is independently 
associated with albuminuria in the population-
based Colaus study 
Franziska Marti 1, Peter Vollenweider2, Pedro-Manuel Marques-Vidal 1•3, Vincent Mooser4, Gérard Waeber2, 
Fred Paccaud 1 and Murielle Bochud 1* 
Abstract 
Background: lncreased serum levels of hornocysteine and uric acid have each been associated with cardiovascular 
risk. We analyzed whether hornocysteine and uric acid were associated with glornerular filtration rate (GFR) and 
albuminuria independenrly of each other. We also investigated the association of MTHFR polyrnorphisrns related to 
homocysteine with albuminuria to get further insight into causality. 
Methods: This was a cross-sectional population-based study in Caucasians (n = 5913). Hyperhomocysteinemia was 
defined as total serum homocysteine ~ 15 µmol/L. Albuminuria was defined as urinary albumin-to-creatinine ratio 
> 30 mg/g. 
Results: Urie acid was associated positively with homocysteine (r = 0.246 in men and r = 0.287 in women, P < 
0.001 ). The prevalence of albuminuria increased across increasing homocysteine categories (from 6.4% to 17.3% in 
subjects with normal GFR and from 3.5% to 14.5% in those with reduced GFR, P for trend < 0.005). 
Hyperhomocysteinemia (OR= 2.22, 95% confidence interval: 1.60-3.08, P < 0.001) and elevated serum uric acid (OR 
= 1.27, 1.08-1.50, per 1 OO µmol/L, P = 0.004) were significantly associated with albuminuria, independently of 
hypertension and type 2 diabetes. The 2-fold higher risk of albuminuria associated with hyperhomocysteinemia 
was similar to the risk associated with hypertension or diabetes. MTHFR alleles related to higher homocysteine 
were associated with increased risk of albuminuria. 
Conclusions: ln the general adult population, elevated serum homocysteine and uric acid were associated with 
albuminuria independently of each other and of renal function. 
Background 
Homocysteine, a sulfor containing amino acid involved 
in methionine metabolism, is a potential atherogenic 
molecule and is considered as an independent risk fac-
tor for cardiovascular disease (CVD) [1-3]. Serum levels 
of total homocysteine (tHcy) are elevated in patients 
with chronic kidney disease (CKD) and, more generally, 
in patients with reduced renal fonction [1,4]. Severa! 
studies have shown that elevated tHcy levels are asso-
ciated with atherothrombotic disease in coronary, cere-
bral and peripheral arteries [3,5]. A similar phenotype is 
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associated with CKD [6,7]. Similar pathological changes 
are observed in glomerular injury and tHcy-induced vas-
cular damages, such as endothelial dysfonction, cell pro-
liferation, increased oxidative stress and prothrombotic 
state [8,9]. As a consequence, high tHcy levels may 
potentially induce renal injury via direct action on kid-
ney cells, rather than only result as a consequence of 
impaired renal fonction. ln other words, tHcy could be 
involved as a cause of renal atherosclerosis and renal 
damage, leading to a vicious cycle with accelerated dete-
rioration of renal function. 
To date, tHcy has been associated with microalbumi-
nuria in population-based studies [l,10,11] and in diabetic 
patients [10,12,13]. The population-based Hoorn study, 
which included subjects aged 50 to 75 years, found that 
() BioMed Central © 2011 Marti et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (httpJ/creativecommons.org/llcenses/by/2.0), whlch permits unrestricted use, distribution, and reproduction in 
any medium, provided the original work is properly cited. 
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baseline tHcy was associated with microalbuminuria not 
only at baseline [10], but also after a mean follow-up of 
6.1 years, independently of renal function [11). In the 
National Health and Nutrition Examination Survey 1991-
1994, the largest population-based study available so far 
(3387 subjects aged ~ 40 years), elevated tHcy was asso-
ciated with albuminuria independently of vitamin B status 
[l]. However, it remains unclear whether tHcy causes 
albuminuria or is merely the consequence of reduced 
renal fonction, which is itself retlected by albuminuria 
[14-). As albuminuria is an established marker of kidney 
damage in diabetlc and nondiabetlc individuals and a 
strong predictor of cardiovascular morbidity and mortality 
[15,16], a better understanding of the determinants of 
albuminuria is therefore of great interest. 
Serum uric acid (SUA) is associated with increased risk 
of incident kidney disease [17], and it also predicts mor-
tallty in patients with CKD [18]. Severa! studies have 
shown a link between SUA concentrations and tHcy 
[19,20). The extent to whlch tHcy and SUA may inde-
pendently influence renal fonction and renal damage is 
not known. Although the association of renal fonction 
and tHcy levels is well-known in selected clinical samples 
[21]. only few large scale population-based data have 
been published so far [1,10]. To our knowledge none of 
the latter investigated the role of SUA in this context. 
The aim of this study was to evaluate the association 
between elevated tHcy and the presence of impaired 
renal fonction, expressed as either decreased glomerular 
filtration rate (GFR) or albuminuria in a large popula-
tion-based sample in Switzerland. We also investigated 
the potential modifying effect of SUA on these relation-
ships. In order to evaluate whether the association 
between tHcy and albuminuria could be causal, we 
looked at the association between albuminuria and the 
methylenetetrahydrofolate reductase (MTHFR) gene 
polymorphisms strongly correlated with tHcy. 
Methods 
Study population 
The CoLaus Study has been described previously [22]. 
Briefly, a simple non-stratified random sample of 35% of 
the overall population of the city of Lausanne, Switzer-
land, aged 35-75 years (n = 56,694) was drawn. Inclu-
sion criteria were: a) written informed consent; b) age 
between 35 and 75 years; c) Caucasian origin. Out of 
the 6188 participants, we excluded 145 subjects because 
of various missing values, leaving 5913 subjects for the 
present analysis. 
The study was approved by the ethical committee of 
the Faculty of Medicine of the University of Lausanne 
(Switzerland) and the research conformed to the Hel-
sinki Declaration. Ali participants provided written 
informed consent. 
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Assessment process and data collection 
Participants attended the outpatient clinlc of the Univer-
sity Hospital Center of Lausanne (CHUV) in the morn-
ing after an overnight fast. BMI was defined as weight 
in kilograms divided by height in meters squared (kg/ 
m2). Blood pressure was measured three times on the 
left arm using a clinically validated automatlc oscillo-
metric devlce [23]Hypertension was defined as a mean 
systolic blood pressure 2 140 mmHg and/or a diastolic 
blood pressure ~ 90 mmHg and/or presence of antihy-
pertensive drug treatment. 
Biological data 
A venous blood sample (50 ml) was collected from each 
participant under fasting conditions. The analytical pro-
ced ures for biological markers and clinicat chemistry 
methods have been described previously [22]. Hyperho-
mocysteinemia was defined as a tHcy level ~ 15 µmol/L 
[1). Diabetes was deflned as a fasting blood glucose ~ 7 
mmol/l and/or presence of any antidiabetic drug 
(including insulin). 
A spot urine sample was collected for the assessment 
of urinary creatinine and albumin, and the ACR was cal-
culated. Albuminuria was defined as a value of ACR 
above 30 mg/g, which includes microalbuminuria (ACR 
30-300 mg/g) and macroalbuminuria (ACR > 300 mg/g) 
[24). Glomerular filtration rate (GFR) was estimated by 
the simplified MDRD prediction equation: GFR (ml/ 
min/1.73 m2) = 186 x (Sçr)"l.154 x (Age)"0·203 x (0.742 if 
female), where Ser is serum creatinine concentration in 
mg/dL and age is in years [25]. We also conducted sen-
sitivity analyses using the Cockcroft-Gault formula to 
estimate creatinine clearance (Cç,): Cç, = (140 - age) x 
(weight)/72 x Ser x (0.83 if female), where Sç,. is in mg/ 
dL, weight in kg and age in years [26). 
Questionnaire data 
Trained health professionals used standardized question-
naires on socio-demographic characteristics and lifestyle 
factors, such as tobacco, alcohol consumption and vita-
min intake. Participants were asked whether they were 
taking vitamin supplements on a regular basis and if 
yes, whlch type of vitamins. No specific information 
allowing differentiating intakes of vitamin B6, Bll and 
Bl2 was collected. For the purpose of the present ana-
lyses, smokers were defined as current smokers and 
non-smokers as never- or ex-smokers. Alcohol con-
sumption was converted in standard units per day. 
Genotyplng and quality controls 
Nuclear DNA was extracted from whole blood for entire 
genome scan analysis. Genotyping was performed using 
the Affymetrix 500 K chip, as recommended by the 
manufacturer. Individuals with Jess than 95% genotyping 
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efficiency overall (or < 90% efficiency on either array, n 
= 399), and individuals with possible gender inconsisten-
cies (n = 5), were removed. Monomorphic single 
nucleotide polymorphisms (SNPs), SNPs with Jess than 
70% genotyping efficiency, SNPs with minor allele fre-
quency < 2% and SNPs not in Hardy-Weinberg propor-
tions were excluded from analyses, leaving at the end 
4155 participants for the present genetic analysis. We 
analyzed the 38 genotyped SNPs located within and 
around (500 kb) the MTHFR gene for association with 
tHcy, using multiple linear regression. Because of its 
known clinical interest, the functional non-synonymous 
MTHFR C677T polymorphism (1û801133) [27) was also 
included in the analysis, even though it was only 
imputed. Imputation was done based on HapMap Phase 
II haplotypes using the IMPUTE software, as previously 
described [28). Three of the genotyped SNPs were 
strongly associated with tHcy levels (rs9651118, R2 = 
0.51%, P = 2 x 10-7 ; rs1321073, R2 = 0.45%, P = 7 x 10-
7 and rs34175640, R2 = 0.45%, P = 7 x 10"7), as was the 
imputed C677T polymorphism (rs1801133, R2 = 0.57%, 
P = 9 x 10"7). Out of the three genotyped SNPs, two 
were in perfect linkage disequilibrium (rs1321073 and 
rs34175640), leaving only three partially independent 
SNPs for the present analysis: rs1321073, rs9651118 and 
rs1801133. 
Statistical analyses 
Statistical analyses were performed using Stata 10.0 
(Stata Corp, College Station, USA). Results were 
expressed as mean ± standard deviation (sd), median ± 
interquartile range or median ± standard error (se). For 
comparison of data between groups, we used a t-test for 
continuous variables and a chi square test for dichoto-
mous variables. We used a non parametric test (nptrend 
in Stata) to test for iinear trend across selected cate-
gories whenever appropriate. We analyzed the associa-
tion between tHcy and SUA using a spearman rank 
correlation test. For descriptive purposes, we split tHcy 
into 4 categories (tHcy < 9, 9 s tHcy < 12, 12 s tHcy < 
15, and tHcy ~ 15 µmol/L), as previously published [1). 
MDRD was dichotomized into < 90, and ~ 90 mL/min/ 
1.73 m2 categories. We used median regression to ana-
lyze the association of MDRD with tHcy (dependent 
variable), white adjusting for the potential confounding 
effect or effect modification of selected covariates. A P-
value < 0.05 was considered as statistically significant 
for mean effects. We systematically tested al! two-way 
interactions of MDRD with ail other covariates in the 
mode!. We used a Bonferroni-corrected P-value to select 
which interaction terms to keep in the mode! (e.g. if 10 
interaction terms were tested, we used 0.005 as a eut-off 
P-value, etc). To keep the models hierarchically sound, 
covariates included in a significant interaction term 
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were kept as main effects in the mode!. To ease inter-
pretation of the significant interaction terms on tHcy, 
we also conducted stratified analyses by age (below vs 
above the mean age of 53 years) and by serum uric acid 
strata (below vs above the mean level of 321 µmol/L). 
We used multiple logistic regression to analyze the asso-
ciation of hyperhomocysteinemia with dichotomized 
albuminuria. We systematically tested ail two-way inter-
actions between hyperhomocysteinemia or sex, on the 
one side, and ail other covariates in the mode!, on the 
other side, and used a Bonferroni-corrected P-value to 
select interaction terms to be kept in the model. We 
analyzed the association of the SNPs with albuminuria 
using logistic regression with an additive mode of 
action. The corresponding P-values are not adjusted for 
multiple testing. 
Results 
Among the 5913 participants aged 35-75 years, with a 
mean (± sd) age at 53 years (± 11 years), 52.5% were 
females. Table 1 displays participants' characteristics 
stratified by sex. Men were significantly younger than 
women, reported higher alcohol consumption and lower 
intake of B vitamins. Men had higher body mass index 
(BMI), blood pressure, Modification of Diet in Rena! 
Disease (MDRD, estimation of GFR), fasting plasma glu-
cose, and SUA levels. Men also had a higher prevalence 
of type 2 diabetes, smoking, hypertension and albumi-
nuria than women. Women had significantly lower tHcy 
levels (9.3 (2.7) µmol/L vs. 10.9 (3.1) µmol/L, P < 0.001) 
and prevalence of hyperhomocysteinemia (4.13% vs. 
10.7%, P < 0.001) than men. tHcy levels were positively 
correlated with SUA in men (r = 0.246, P < 0.001) and 
in women (r = 0.287, P < 0.001). 
In multiple regression analysis using tHcy as the 
dependent variable, the association of MDRD with tHcy 
was modified by age and SUA (Table 2, P for interaction 
< 0.001) after adjusting for major confounding factors. 
When conducting stratified analyses, the regression 
coefficient for MDRD on tHcy was -0.043 [95%CI: 
-0.050; -0.036) and -0.060 (-0.066; -0.054] in the younger 
and older age groups, respectively, and -0.042 [95%CI: 
-0.048; -0.036) and -0.057 [-0.064; -0.049) for the low 
and high uric acid groups, respectively. To ease the 
interpretation of these findings, Figure 1 shows the 
adjusted median tHcy levels by MDRD and age groups. 
Within each group, tHcy was more elevated in the high 
SUA category than in the low SUA category. Sensitivity 
analyses using the Cockcroft-Gault formula led to simi-
lar results. 
ln multiple logistic regression, hyperhomocysteinemia 
(tHcy ~ 15 µmol/L) (OR = 2.22, 95% confidence interval 
(CI): 1.60-3.08, P < 0.001) and SUA (OR = 1.27, 95%CI: 
1.08-1.50, per 100 µmol/L P = 0.004) were significantly 
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Table 1 Participants' characteristlcs by sex 
Characterlstics Men 
(n = 2766) 
Age (years) .52.4 (10.7) 
Alcohol consumption (units/day) 1.49 (1.57) 
Smokers (%) 28.3 
lntake of B vitamins (%) 5.8 
Use of diuretics (%) 6.9 
Body mass index (kg/m2) 26.6 (4.0) 
Type 2 diabetes (%) 9.2 
Hypertension (%) 41.5 
Systolic blood pressure (rnmHg) 132.0 (16.5) 
Diastolic blood pressure (mmHg) 81.2 (10.7) 
Hyperhomocystelnemia (%) 10.7 
Serum measurements 
Total homocysteine (µmol/L) 10.9 (3.1) 
Creatinlne (µmol/L) 88.1 (15.6) 
MDBD ' (rnl/rnin/1.73 m~ b 85.9 (20.0) 
Urie acld (µmol/L) 360.4 (74.8) 
Total cholesterol (mrnol/L) 5.56 (1.04) 
HDL-cholesterol (mrnol/L) 1.44 (0.36) 
Fasting glucose (mmol/L) 5.78 (1.23) 
Urine measurements 
Albumin to creatinine ratio (mg/g) ' 4.56 (5.26) 
Albuminuria ' (%) 6.9 
Women 
(n = 3147) 
53.4 (10.7) 
0.57 (0.80) 
24.9 
8.9 
6.4 
25.1 (4.8) 
3.5 
29.8 
124.7 (18.2) 
77.5 (10.5) 
4.13 
9.27 (2.7) 
72.0 (11.6) 
79.3 (18.6) 
269.9 (66.4) 
5.61 (1.03) 
1.81 (0.42) 
5.34 (0.99) 
5.58 (5.88) 
5.4 
Dota are expressed os mean (standard devlatlon), n (%) or median ' 
(interquartile range). 
" Modification of Dlet ln Renol Diseose, estimation of glomerular filtration rate 
' urinary albumln-to-creatlnlne ratio > 30 mg/g 
Table 2 Determlnants of total serum homocystelne 
~-Coefficient 95% Cl d 
Sex (0 = men, 1 = women) -1.341 -1.540 ·1.141 e 
Age (years) 0.136 0.097 0.176" 
Alcohol consumption (units/day) 0.098 0.034 0.162. 
Smoking status 0.468 0.291 0.645 e 
lntake of B vitamins -0.616 -0.904 ·0.328 e 
Use of diuretics 0.394 0.072 0.716 e 
Body mass index (kg/m2) -0.019 -0.038 0.001 
Systolic blood pressure (rnmHg) 0.006 0.001 0.011 e 
Total serum cholesterol (mmol/L) 0.030 -0.046 0.105 
Plasma lasting glucose (mmol/L) -0.023 -0.096 0.050 
Serum uric acid (µmol/L) 0.014 0.009 0.019 e 
MORD • (ml/min/1.73 m2) 0.037 0.010 0.064 e 
MDRD x age b -0.0010 -0.0015 -0.0006. 
MORD x uric acid ' -0.00011 -0.00016 -0.00005 e 
' Modification of Diet in Renal Disease, estimation of glomerular filtration rate 
b Interaction between MORD and age 
'Interaction between MORD and serum uric acid 
• 95% Confidence lnterval 
' P value < 0.05 
Total serum homocystelne 
(f1mol/L) 
12.0 
11.0 
10.0 
9.0 
8.0 
7.0 
n=1183 
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mllmln/1.73 m2 
MORD>= 90 
mllmln/1.73 m2 
Figure 1 Total serum homocysteine levels by categorles of 
MDRD, age and urlc acid levels. Bars (whiskers) are medians (se) 
adjusted for sex, categories of age, MORD and serum uric acid 
levels. P-values for age, MORD and serum urlc acld categories < 
0.001 from a multiple median regression using total serum 
homocysteine as the dependent variable. MORD, Modification of 
Die\ in Rena! Disease, estimation of glornerular filtration rate. 
related with albuminuria independently of hypertension 
and diabetes (Table 3). The risk of albuminuria asso-
ciated with hyperhomocysteinemia (OR = 2.22, 95%CI: 
1.60-3.08, P < 0.001) was similar to that associated with 
hypertension (OR = 1.52, 95%CI: 1.11-2.09, P = 0.009) 
or with type 2 diabetes (OR = 1.93, 95%CI: 1.27-2.91, P 
= 0,002), We found no significant interaction between 
hyperhomocysteinemia and any of the covariate in the 
mode!, including SUA, Further adjustment for ACE 
inhibitor and angiotensin receptor blocker treatment did 
not substantially modify the association of hyperhomo-
cysteinemia with albuminuria (OR = 2.18, 95%CI: 1.57-
3.04), while decreasing the association of hypertension 
with albuminuria (OR= 1.39; 95%CI: 0.99-1.96), 
The prevalence of albuminuria was gradually higher 
across increasing tHcy categories (Figure 2). A similar 
trend was observed in subjects with normal GFR levels 
(6.4%, 4.6%, 9.7% and 17.3%, P for trend < 0.005) and in 
subjects with decreased GFR levels (3.5%, 5.0%, 8.3% 
and 14.5%, P for trend < 0.005), Results were similar in 
men and in women (data not shown). 
In the subsample of the study population in which 
genotyping was performed, we analyzed the association 
of three MTHFR polymorphisms related to tHcy levels 
with albuminuria (Figure 3). After adjustment for major 
confounding factors, the risk of albuminuria increased 
significantly from the AA to the GG genotype (OR = 
1.28, 95%CI: 1.04-1.58 per G allele, P = 0.021) for the 
rs1321073 SNP. A similar trend was observed for 
6 
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Table 3 Determinants of albuminuria 
Albumlnurla a Odds Ratio 95% Cl c P-values 
Smoking status (1 = current smoker, 0 = non-smoker) 1.35 1.05. 1.74 0.018 
lntake of B vitamins (1 = intake, o = no intake) 1.09 0.70. 1.69 0.700 
MDRD b (ml/min/1.73 m2) 1.005 0.997 • 1.013 0.219 
Type 2 diabetes 1.93 1.27 - 2.91 0.002 
Fasting glucose (mmol/L) 1.22 1.12 - 1.33 < 0.001 
Hypertension 1.52 1.11 - 2.09 0.009 
Systolic blood pressure (mm Hg) 1.01 1.01 - 1.02 < 0.001 
Serurn une acid (per 100 µmol/L) 1.27 1.08. 1.50 0.004 
Hyperhomocysteinemia 2.22 1.60 - 3.08 < 0.001 
Loglstlc regresslon mode! lncluding age, sex, body mass Index and age x sex Interaction as addltlonal covarlates. 
' urlnary albumln-to-creatinine ratio > 30 mg/g 
b Modification of Diet in Renal Disease, estimation of glomerular filtration rate 
' 95% Confidence lnterval 
rs1801133 (OR = 1.20, 95%CI: 0.99-1.46 per T allele, P = 
0,068), but the association was not significant for 
rs9651118 (OR = 1.12, 95%CI: 0.89-1.42 per T allele, P 
= 0.344). In non-diabetic subjects, the association 
between albuminuria and both rs1321073 (OR = 1.31, 
95%CI: 1.04-1.64 per G allele, P = 0.023} and rs1801133 
(OR = 1.30, 95%CI: 1.05-1.61 per T allele, P = 0.017} 
was significant. A similar trend was observed for 
rs9651118 (OR = 1.11, 95%CI: 0.86-1.45 per T allele, P 
= 0.417), although not reaching significance. In type 2 
diabetic subjects, these polymorphisms were associated 
neither with tHcy nor with albuminuria. 
Discussion 
In this large population-based study, the association 
between elevated tHcy levels and higher prevalence of 
albuminuria was observed independently of GFR, reflect-
ing the fact that this association is not simply the 
Prevatence or 
albumlnurla (%) 
20 P trend < 0.005 
16 
16 n=346 
14 u 12 
·; "[(Ô n 
< 9 9-12 12-15 >=15 
Total serum hornocystelne categories 
MORD <90 
mVmln/1.73 m' 
P trend < 0.005 
n=81 
nu=196 ~ n=970 D "ô1 
< 9 9-12 12-15 >=16 
Total serum homocystelne categorles 
MORD >=90 
ml/mln/1,73 m' 
Figure 2 Prevalence (95%CI) of albumlnurla by categorles of 
MORD and total serum homocystelne. Results were sirnllar in 
men and in women. We assessed trend across total serurn 
homocysteine categories uslng non-parametric test. MDRD, 
Modification of Dlet in Renal Disease, used to estlrnate glomerular 
filtration rate. 
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consequence of reduced renal function. This result is 
consistent with the hypothesis that homocysteine may 
cause renal damage. We extend previous population-
based findings [1,10,11) to the age group 35-40 years. 
Also, the association of hyperhomocysteinemia with 
albuminuria was independent of hypertension, type 2 
diabetes and uric acid levels. Furthermore, hyperhomo-
cysteinemia was associated with a 2-fold higher risk of 
albuminuria, which was of similar magnitude to the risk 
of albuminuria associated with hypertension or type 2 
diabetes. This result strongly suggests that hyperhomo-
cysteinemia is an independent marker of renal dysfunc-
tion and is in line with the role of homocysteine as 
potential atherogenic agent and cardiovascular risk fac-
tor [2). 
We observed strong associations between homocys-
teine levels and MTHFR polymorphisms, as previously 
reported [29-31). This suggests that MTHFR genotypes 
related to higher homocysteine levels are associated 
with albuminuria in the general population, in particu-
lar in non-diabetic subjects. Because of the random 
assortment of alleles at the time of gamete formation, 
association between MTHFR genotypes and tHcy 
levels, or albuminuria, should not be biased by reverse-
causality or major confounding factors. These results 
therefore suggest that homocysteine might be causally 
involved in renal damage. MTHFR polymorphisms 
have been shown to be associated with increased mor-
tality and morbidity in healthy and CKD populations 
[29-31]. Sorne studies in diabetic patients found the 
C677T polymorphism (rsl801133} to be associated 
with renal damage [32-36], but others failed to find 
such association [37,38]. In this study, rs1321073 was 
significantly associated with the risk of albuminuria in 
the general population, independently of major con-
founding factors. However, this latter association was 
not significant in type 2 diabetic subjects, in whom no 
association with tHcy was observed. First of ail, the 
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A 
B. 
Total serum 
homocysteine 
(µmol/I) 
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0.6 
0.4 
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p < 0.001 
rs1321073 
p = 0.021 
G allele 
rs1321073 
p < 0.001 
rs1801133 
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T allele 
Additive risk allele 
rs1801133 
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p < 0.001 
2645 
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p = 0.344 
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Figure 3 Adjusted Odds Ratios (OR) for the rlsk of albuminuria by MTHFR gene polymorphisms. Genetie analysis was performed in a 
subgroup of study (n = 4155). OR were adjusted for age, sex, smoking, alcohol consumption, lntake of vitamin B, body mass Index, 
hypertension, systolic blood pressure, type 2 diabetes, plasma fasting glucose, total cholesterol, serum uric acid and glomerular filtration rate. A. 
Median unadjusted total serum homocysteine level by genotype for each MTHFR polymorphism.B. Adjusted odds ratio for the risk of 
albuminuria per risk allele (additive model). 
number of diabetics was smalL Second, since diabetes 
itself represents a major cause of albuminuria, the 
effect of homocysteine on renal damage might not be 
easily detectable in this subgroup, as reflected by the 
conflicting results reported in studies restricted to dia-
betic patients [32-38]. Results for the nonsynonymous 
rs 1801133 (C677T) SNP, which is associated with 
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reduced MTHFR activity [27], were quite similar. 
Although associated with tHcy levels, rs9651118 was 
not significantly associated with albuminuria, but the 
effect was nevertheless in the same direction. As each 
SNP only explained a tiny fraction of homocysteine 
variance, this study might have reduced power to 
detect this association, 
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ln line with previous reports, we found a positive 
association between SUA and tHcy [19]. However, SUA 
did not modify the relationship between tHcy levels and 
albuminuria. This suggests that there is no strong syner-
gistic or antagonistic effect between homocysteine and 
uric acid for their effect on renal damage, but rather 
that both factors act independently on albuminuria. 
Conversely, we observed an effect modification of uric 
acid on the known negative association between tHcy 
levels and GFR, independently of major confounding 
factors. We are not aware that the effect modification of 
SUA on the association between tHcy and renal fonc-
tion has been previously reported. Both hyperuricemia 
and hyperhomocysteinemia are common findings in 
patients with CKD. In prospective studies among CKD 
patients, baseline SUA and baseline tHcy levels appeared 
to predict overall mortality [4,18]. However the link 
between tHcy, SUA and decreased renal function is 
unclear. A possible explanation is that antioxidants, like 
uric acld, raise in reaction to increased oxidative stress 
to counteract the harmfol effect of reactive oxygen spe-
cies induced by elevated homocysteine [8]. Reactlve oxy-
gen species reduce glomerular blood flow and filtration 
rate by release of vasoconstrictors and, possibly by inac-
tivation of NO [39]. 
Hyperhomocysteinemiu is frequent in patients with 
CKD [1,4). In this study, tHcy was higher whenever 
renal function was decreased. This might result, in part, 
from the fact that impaired renal fonction reduces the 
renal clearance of homocysteine. This could also result, 
in part, from impaired intrarenal homocysteine metabo-
lism, impaired extrarenal homocysteine metabolism or 
both. Also the prevalence of albuminuria was gradually 
higher with increasing tHcy levels, independently of glo-
meru lar filtration rate, since a similar trend was 
observed after stratifying for normal and decreased GFR 
levels. Severa! prospective studies have shown that 
hyperhomocysteinemia is an independent determinant 
of the development of CKD and albuminuria in the gen-
eral population [11,40]. Moreover, in a prospective 
study, kidney transplant recipients with elevated tHcy 
levels at baseline had a greater risk of death and kidney 
allograft Joss [4]. These findings forther support the 
concept that tHcy is not merely a marker, but rather a 
predictor of CVD. CVD currently represents the main 
cause of death in CKD patients, with mortality rates 
three to 30 times higher than expected [6,41]. As this 
high mortality is only partly explained by CVD risk fac-
tors, such as hypertension, diabetes, smoking and dysli-
pidemia, factors such as hyperhomocysteinemia and 
elevated uric acid levels may play a role. 
Our study has several limitations. Unfortunately, we 
have no data on vitamin status, including folie acid, vita-
min B6, and vitamin B12, but we could include data on 
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reported vitamin B intake. However, several previous stu-
dies observed no significant interaction of vitamin B sta-
tus on the association between tHcy and renal fonction 
or tHcy and cardiovascular risk [1,42]. We used estima-
tions of GFR by the MDRD formula in thls study. As 
MDRD has not been validated in populations with nor-
mal GFR, we also conducted sensitivity analyses using 
GFR estimated by the Cockcroft-Gault formula, which 
led to similar results. The calculated GFR and albumin-
to-creatinine ratio (ACR) were based on a single mea-
surement, as in previous population-based studies [1,10]. 
tHcy was also based on one single measure and is there-
fore insufficient to predict life-time exposure. Despite the 
small proportion of homocysteine variance explained, 
MTHFR polymorphisms may better reflect the life-time 
exposure to tHcy. However, our study also has several 
strengths. lt is to our knowledge the largest population-
based study exploring associations between homocysteine 
and renal function, hence with a wide external validity. A 
longitudinal follow-up of ail participants in the CoLaus 
study is currently ongoing and shall provide essential 
data for trends over tilne of major cardiovascular risk fac-
tors according to baseline homocysteine levels. 
Conclusions 
In conclusion, hyperhomocysteinemia was associated 
with higher prevalence of albuminuria in men and in 
women, independently of renal fonction. The association 
of hyperhomocysteinemia with albuminuria was not only 
independent of type 2 diabetes and hypertension, but 
also as strong as the one found for these two conditions, 
which are major causes of albuminuria. Individuals car-
rying MTHFR genotypes associated with higher tHcy 
concentrations were at increased risk for albuminuria. 
This latter finding supports the hypothesis that homo-
cysteine causes renal damage. Further studies are needed 
to explore whether lowering serum homocysteine levels 
might prevent kidney damage. Serum uric acid was also 
associated with albuminuria, independently of homocys-
teine. Although uric acid modified the association of 
tHcy with GFR, no such effect modification was 
observed for the association between hyperhomocystei-
nemia and albuminuria, which speaks against a strong 
synergistic or antagonistic effect between homocysteine 
and uric acid on renal damage. 
List of abbreviatlons used 
ACR: albumin-to·creatinine ratio; BMI: body mass index; CKD; chronic kidney 
disease; CVD: cardiovascular disease; GFR: glomerular filtration rate; MTHFR: 
methylenetetrahydrofolate reductase; SUA: Serum uric acid; tHcy: total 
homocysteine. 
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